Abstract
Between November 1993 and June 1995 18 patients received oral famciclovir (3 × 500 mg) for treatment of hepatitis B virus (HBV) reinfection after liver transplantation. Reinfection was defined as the reoccurrence of HBsAg in the serum. In the first 15 patients, famciclovir therapy was initiated after clinical signs of graft hepatitis, whereas the last 3 patients received treatment immediately after HBV-DNA was detected. Famciclovir was well-tolerated in all patients. HBV-DNA values were decreased to undetectable levels in 8 out of 18 patients. Clinical status improved in 7 patients, whereas 5 patients remained unchanged and 6 patients progressed to deteriorating graft function and death. When famciclovir was initiated early after reinfection, a response rate of approximately 66% was observed. Late onset of therapy in patients with fulminant hepatitis generally failed to provide any clinical benefit.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Neuhaus P, Steffen R, Blumhardt G, Bechstein WO, Keck H, Lemmens HP, Neuhaus R, Lobeck H, König V, Hopf U (1991) Experience with immunoprophylaxis and interferon therapy after liver transplantation in HBsAg positive patients. Transplant Proc 23: 1522 - 1524
Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou J-P, Bismuth H (1993) Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 329: 1842 - 1847
Freeman RB, Sanchez H, Lewis WD, Sherburne B, Dzik WH, Khettry U, Hing S, Zeldis JB, Jenkins RL (1991) Serologic and DNA follow-up data from HBsAgpositive patients treated with orthotopic liver transplantation. Transplantation 51: 793 - 797
Lucey MR, Graham DM, Martin P, Di Bisceglie A, Rosenthal S, Waggoner JG, Merion RM, Campbell DA, Nostrant TT, Appelman HD (1992) Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation. Gut 33: 1390-1396
Müller R, Gubernatis G, Farle M, Niehoff G, Klein H, Wittekind C, Tusch G, Lautz H-U, Böker K, Stangel W, Pichlmayr R (1991) Liver transplantation in HBs antigen (HBsAg) carriers: prevention of hepatitis B virus ( HBV) recurrence by passive immunization. J Hepatol 13: 90-96
Vere Hodge RA, Sutton D, Boyd MR, Harnden MR, Jarvest RL (1989) Selection of an oral prodrug (BRL 42810; famciclovir) for the anti-herpes virus agent BRL 39123 [9-(4-hydroxy-3-hy-droxymethylbut-l-yl)guanine; penciclovir]. Antimicrob Agents Chemother 33: 1765 - 1773
Korba BE, Milman G (1991) A cell culture assay for compounds which inhibit hepatitis B virus replication. Antiviral Res 15: 217 - 228
Tsiquaye KN, Slomka MJ, Maung M (1994) Oral famciclovir against duck hepatitis B virus replication in hepatic and nonhepatic tissues of ducklings infected in vivo. J Med Virol 42: 306 - 310
Bäcker KHW, Ringe B, Krüger M, Pichlmayr R, Manns MP (1995) Prostaglandin E plus famciclovir — a new concept for treatment of severe hepatitis B after liver transplantation. Transplantation 57: 1706 - 1708
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Haller, G.W. et al. (1996). Famciclovir therapy for recurrent hepatitis B virus infection after liver transplantation. In: Mühlbacher, F., et al. Transplant International . Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-00818-8_53
Download citation
DOI: https://doi.org/10.1007/978-3-662-00818-8_53
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-61024-3
Online ISBN: 978-3-662-00818-8
eBook Packages: Springer Book Archive